{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T18:30:46Z","timestamp":1740162646209,"version":"3.37.3"},"reference-count":38,"publisher":"BMJ","issue":"4","funder":[{"DOI":"10.13039\/501100000664","name":"Health\n                                    Technology Assessment Programme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"published-print":{"date-parts":[[2018,4]]},"abstract":"<jats:sec>\n                        <jats:title>Introduction<\/jats:title>\n                        <jats:p>Vitiligo is a condition resulting in white patches on the skin.\n                            People with vitiligo can suffer from low self-esteem, psychological\n                            disturbance and diminished quality of life. Vitiligo is often poorly\n                            managed, partly due to lack of high-quality evidence to inform clinical\n                            care. We describe here a large, independent, randomised controlled trial\n                            (RCT) assessing the comparative effectiveness of potent topical\n                            corticosteroid, home-based hand-held narrowband ultraviolet B-light\n                            (NB-UVB) or combination of the two, for the management of\n                            vitiligo.<\/jats:p>\n                    <\/jats:sec>\n                    <jats:sec>\n                        <jats:title>Methods and analysis<\/jats:title>\n                        <jats:p>The HI-Light Vitiligo Trial is a multicentre, three-arm, parallel\n                            group, pragmatic, placebo-controlled RCT. 516 adults and children with\n                            actively spreading, but limited, vitiligo are randomised (1:1:1) to one\n                            of three groups: mometasone furoate 0.1% ointment plus dummy NB-UVB\n                            light, vehicle ointment plus NB-UVB light or mometasone furoate 0.1%\n                            ointment plus NB-UVB light. Treatment of up to three patches of vitiligo\n                            is continued for up to 9 months with clinic visits at baseline, 3, 6 and\n                            9 months and four post-treatment questionnaires.<\/jats:p>\n                        <jats:p>The HI-Light Vitiligo Trial assesses outcomes included in the\n                            vitiligo core outcome set and places emphasis on participants\u2019 views of\n                            treatment success. The primary outcome is proportion of participants\n                            achieving treatment success (patient-rated Vitiligo Noticeability Scale)\n                            for a target patch of vitiligo at 9 months with further independent\n                            blinded assessment using digital images of the target lesion before and\n                            after treatment. Secondary outcomes include time to onset of treatment\n                            response, treatment success by body region, percentage repigmentation,\n                            quality of life, time-burden of treatment, maintenance of response,\n                            safety and within-trial cost-effectiveness.<\/jats:p>\n                    <\/jats:sec>\n                    <jats:sec>\n                        <jats:title>Ethics and dissemination<\/jats:title>\n                        <jats:p>Approvals were granted by East Midlands\u2014Derby Research Ethics\n                            Committee (14\/EM\/1173) and the MHRA (EudraCT 2014-003473-42). The trial\n                            was registered 8 January 2015 ISRCTN (17160087). Results will be\n                            published in full as open access in the NIHR Journal library and\n                            elsewhere.<\/jats:p>\n                    <\/jats:sec>\n                    <jats:sec>\n                        <jats:title>Trial registration number<\/jats:title>\n                        <jats:p><jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"ISRCTN17160087\" ext-link-type=\"isrctn\" specific-use=\"clinicaltrial\">ISRCTN17160087<\/jats:ext-link>.<\/jats:p>\n                    <\/jats:sec>","DOI":"10.1136\/bmjopen-2017-018649","type":"journal-article","created":{"date-parts":[[2021,7,10]],"date-time":"2021-07-10T02:25:15Z","timestamp":1625883915000},"page":"e018649","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":5,"title":["Home interventions and light therapy for the treatment of vitiligo\n                        (HI-Light Vitiligo Trial): study protocol for a randomised controlled\n                        trial"],"prefix":"10.1136","volume":"8","clinical-trial-number":[{"clinical-trial-number":"isrctn17160087","registry":"10.18810\/isrctn"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7924-0602","authenticated-orcid":false,"given":"Rachel H","family":"Haines","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7785-7465","authenticated-orcid":false,"given":"Kim S","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan A","family":"Montgomery","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane C","family":"Ravenscroft","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Perways","family":"Akram","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanne R","family":"Chalmers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diane","family":"Whitham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lelia","family":"Duley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viktoria","family":"Eleftheriadou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Garry","family":"Meakin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eleanor J","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"White","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andy","family":"Rogers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tracey","family":"Sach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7264-5260","authenticated-orcid":false,"given":"Miriam","family":"Santer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Trish","family":"Hepburn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hywel C","family":"Williams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Batchelor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2018,4,3]]},"reference":[{"key":"2021070910485262000_8.4.e018649.1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1977.01640010049006"},{"key":"2021070910485262000_8.4.e018649.2","doi-asserted-by":"publisher","DOI":"10.4103\/0378-6323.32708"},{"key":"2021070910485262000_8.4.e018649.3","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/j.1365-4362.1985.tb05445.x","article-title":"Clinical pattern of vitiligo in Libya","volume":"24","author":"Singh","year":"1985","journal-title":"Int J Dermatol"},{"key":"2021070910485262000_8.4.e018649.4","doi-asserted-by":"publisher","DOI":"10.1002\/gepi.1370020107"},{"key":"2021070910485262000_8.4.e018649.5","doi-asserted-by":"publisher","DOI":"10.1016\/0163-8343(79)90081-1"},{"key":"2021070910485262000_8.4.e018649.6","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1978.01640210075025"},{"key":"2021070910485262000_8.4.e018649.7","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/S0190-9622(86)70160-6","article-title":"Psychosocial effect of vitiligo: a comparison of vitiligo\n                            patients with \"normal\" control subjects, with psoriasis patients, and\n                            with patients with other pigmentary disorders","volume":"15","author":"Porter","year":"1986","journal-title":"J Am Acad Dermatol"},{"key":"2021070910485262000_8.4.e018649.8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2008.08881.x"},{"key":"2021070910485262000_8.4.e018649.9","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2012.11197.x"},{"key":"2021070910485262000_8.4.e018649.10","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1111\/bjd.14356","article-title":"Evidence-based management of vitiligo: summary of a cochrane\n                            systematic review","volume":"174","author":"Whitton","year":"2016","journal-title":"Br J Dermatol"},{"key":"2021070910485262000_8.4.e018649.11","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1001\/jama.2016.12399","article-title":"Interventions for vitiligo","volume":"316","author":"Ezzedine","year":"2016","journal-title":"JAMA"},{"key":"2021070910485262000_8.4.e018649.12","first-page":"CD003263","article-title":"Interventions for vitiligo","volume":"2","author":"Whitton","year":"2015","journal-title":"Cochrane Database Sys Rev"},{"key":"2021070910485262000_8.4.e018649.13","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/phpp.12228","article-title":"Exploring the gaps in the evidence-based application of\n                            narrowband UVB for the treatment of vitiligo","volume":"32","author":"Madigan","year":"2016","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"2021070910485262000_8.4.e018649.14","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/j.1600-0781.2012.00648.x","article-title":"Evaluation of the effect of disease duration in generalized\n                            vitiligo on its clinical response to narrowband ultraviolet B\n                            phototherapy","volume":"28","author":"Hallaji","year":"2012","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"2021070910485262000_8.4.e018649.15","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/1745-6215-15-51","article-title":"Feasibility, double-blind, randomised, placebo-controlled,\n                            multi-centre trial of hand-held NB-UVB phototherapy for the treatment of\n                            vitiligo at home (HI-Light trial: Home Intervention of Light\n                            therapy)","volume":"15","author":"Eleftheriadou","year":"2014","journal-title":"Trials"},{"key":"2021070910485262000_8.4.e018649.16","first-page":"530","article-title":"Future research into the treatment of vitiligo: where should\n                            our priorities lie? Results of the vitiligo priority setting\n                            partnership","volume":"164","author":"Eleftheriadou","year":"2011","journal-title":"Br J Dermatol"},{"key":"2021070910485262000_8.4.e018649.17","first-page":"340","article-title":"Statement: updated guidelines for reporting parallel group\n                            randomised trials","volume":"2010","author":"Schulz","year":"2010","journal-title":"BMJ"},{"key":"2021070910485262000_8.4.e018649.18","unstructured":"Elocon ointment: summary of product characteristics.\n                            2015. www.medicines.org.uk (accessed 23 Dec\n                            2015)."},{"key":"2021070910485262000_8.4.e018649.19","unstructured":"White Soft Parrafin: summary of product\n                            characteristics. 1998\n                            http:\/\/www.mhra.gov.uk\/home\/groups\/spcpil\/documents\/spcpil\/con1369115628367.pdf."},{"key":"2021070910485262000_8.4.e018649.20","unstructured":"McKenna K , Ibbotson S . Principles of phototherapy.\n                            In: Griffiths C , Barker J , Bleiker T , Chalmers R , Creamer D , eds.\n                            Rooks textbook of dermatology. 9th edn. Hoboken, NJ: Wiley-Blackwell,\n                            2016."},{"key":"2021070910485262000_8.4.e018649.21","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1111\/j.1365-2133.2012.11056.x","article-title":"Which outcomes should we measure in vitiligo? Results of a\n                            systematic review and a survey among patients and clinicians on outcomes\n                            in vitiligo trials","volume":"167","author":"Eleftheriadou","year":"2012","journal-title":"Br J Dermatol"},{"key":"2021070910485262000_8.4.e018649.22","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/pcmr.12354","article-title":"Developing core outcome set for vitiligo clinical trials:\n                            international e-Delphi consensus","volume":"28","author":"Eleftheriadou","year":"2015","journal-title":"Pigment Cell Melanoma Res"},{"key":"2021070910485262000_8.4.e018649.23","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/bjd.14208","article-title":"Validation of the vitiligo noticeability scale: a\n                            patient-reported outcome measure of vitiligo treatment\n                            success","volume":"174","author":"Batchelor","year":"2016","journal-title":"Br J Dermatol"},{"key":"2021070910485262000_8.4.e018649.24","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1016\/j.jaad.2012.01.038","article-title":"Development and validation of a vitiligo-specific\n                            quality-of-life instrument (VitiQoL)","volume":"69","author":"Lilly","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"2021070910485262000_8.4.e018649.25","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2012.10806.x"},{"key":"2021070910485262000_8.4.e018649.26","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-011-9903-x"},{"key":"2021070910485262000_8.4.e018649.27","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.jval.2012.04.005","article-title":"Whose values in health? An empirical comparison of the\n                            application of adolescent and adult values for the CHU-9D and AQOL-6D in\n                            the Australian adolescent general population","volume":"15","author":"Ratcliffe","year":"2012","journal-title":"Value Health"},{"key":"2021070910485262000_8.4.e018649.28","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-012-0322-4"},{"key":"2021070910485262000_8.4.e018649.29","doi-asserted-by":"crossref","unstructured":"Stevens K . The Child Health Utility 9D (CHU9D) \u2013 A\n                            new paediatric preference based measure of health related quality of\n                            life. PRO Newsletter 2010.","DOI":"10.1037\/t71525-000"},{"key":"2021070910485262000_8.4.e018649.30","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-009-9524-9"},{"key":"2021070910485262000_8.4.e018649.31","doi-asserted-by":"publisher","DOI":"10.2165\/11587350-000000000-00000"},{"key":"2021070910485262000_8.4.e018649.32","unstructured":"NICE. Guide to the methods of technology appraisal,\n                            2013."},{"key":"2021070910485262000_8.4.e018649.33","doi-asserted-by":"publisher","DOI":"10.1002\/hec.944"},{"key":"2021070910485262000_8.4.e018649.34","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2008.00358.x"},{"key":"2021070910485262000_8.4.e018649.35","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1099-1050(199707)6:4<327::AID-HEC282>3.0.CO;2-W"},{"key":"2021070910485262000_8.4.e018649.36","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1471-5945-14-10","article-title":"Survey and online discussion groups to develop a\n                            patient-rated outcome measure on acceptability of treatment response in\n                            vitiligo","volume":"14","author":"Tour","year":"2014","journal-title":"BMC Dermatol"},{"key":"2021070910485262000_8.4.e018649.37","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/pcmr.12561","article-title":"Repigmentation in vitiligo: position paper of the Vitiligo\n                            Global Issues Consensus Conference","volume":"30","author":"Gan","year":"2017","journal-title":"Pigment Cell Melanoma Res"},{"key":"2021070910485262000_8.4.e018649.38","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.h1258"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2017-018649","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,10]],"date-time":"2021-07-10T02:25:41Z","timestamp":1625883941000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2017-018649"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":38,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2018,4,3]]},"published-print":{"date-parts":[[2018,4]]}},"alternative-id":["10.1136\/bmjopen-2017-018649"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2017-018649","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"type":"print","value":"2044-6055"},{"type":"electronic","value":"2044-6055"}],"subject":[],"published":{"date-parts":[[2018,4]]}}}